Your browser is no longer supported. Please, upgrade your browser.
Settings
LOXO Loxo Oncology, Inc. daily Stock Chart
LOXO [NASD]
Loxo Oncology, Inc.
Index- P/E- EPS (ttm)-2.08 Insider Own7.30% Shs Outstand30.65M Perf Week-3.59%
Market Cap4.15B Forward P/E- EPS next Y-3.26 Insider Trans-43.44% Shs Float27.34M Perf Month-23.23%
Income-63.00M PEG- EPS next Q-0.81 Inst Own99.20% Short Float8.10% Perf Quarter-18.07%
Sales144.80M P/S28.66 EPS this Y-53.30% Inst Trans-0.32% Short Ratio6.58 Perf Half Y-24.66%
Book/sh12.43 P/B10.89 EPS next Y-50.20% ROA-8.70% Target Price203.90 Perf Year70.01%
Cash/sh20.29 P/C6.67 EPS next 5Y37.00% ROE-16.40% 52W Range75.78 - 208.95 Perf YTD60.82%
Dividend- P/FCF18.03 EPS past 5Y- ROI-40.30% 52W High-35.21% Beta2.22
Dividend %- Quick Ratio3.60 Sales past 5Y- Gross Margin- 52W Low78.65% ATR8.90
Employees96 Current Ratio3.60 Sales Q/Q- Oper. Margin-50.30% RSI (14)38.19 Volatility5.85% 6.43%
OptionableYes Debt/Eq0.00 EPS Q/Q63.90% Profit Margin-43.50% Rel Volume0.80 Prev Close135.00
ShortableYes LT Debt/Eq0.00 EarningsNov 08 BMO Payout- Avg Volume336.69K Price135.38
Recom1.70 SMA20-9.03% SMA50-13.97% SMA200-11.97% Volume270,351 Change0.28%
Nov-15-18Initiated Raymond James Strong Buy $235
Sep-25-18Initiated Leerink Partners Outperform
Sep-17-18Initiated Goldman Neutral $165
Aug-10-18Reiterated Stifel Buy $225 → $217
Jun-04-18Reiterated Stifel Buy $190 → $225
May-17-18Reiterated Stifel Buy $145 → $190
Apr-16-18Upgrade Morgan Stanley Equal-Weight → Overweight
Mar-21-18Downgrade Morgan Stanley Overweight → Equal-Weight
Feb-22-18Initiated Oppenheimer Outperform $132
Nov-28-17Initiated William Blair Outperform
Aug-29-17Downgrade JMP Securities Mkt Outperform → Mkt Perform
Jun-05-17Upgrade Citigroup Neutral → Buy
Jun-05-17Reiterated Stifel Buy $52 → $71
Apr-03-17Initiated Morgan Stanley Overweight $59
Mar-10-17Downgrade Citigroup Buy → Neutral
Feb-08-17Initiated Jefferies Buy $50
Mar-16-16Reiterated Stifel Buy $37 → $36
Jan-15-16Initiated Citigroup Buy $32
Nov-11-15Reiterated Stifel Buy $26 → $37
Sep-02-14Initiated Stifel Buy $20
Dec-10-18 12:24PM  Is Loxo Oncology Inc (LOXO) A Good Stock To Buy? Insider Monkey
Nov-29-18 08:00AM  Recent Analysis Shows Mid-America Apartment Communities, Loxo Oncology, Arista Networks, ADT, Welltower, and First Majestic Silver Market Influences Renewed Outlook, Key Drivers of Growth GlobeNewswire
Nov-28-18 08:31AM  5 Things You Need to Know About Loxo Oncology's Revolutionary New Cancer Drug Motley Fool
07:00AM  Todays Research Reports on Stocks to Watch: Loxo Oncology and ACADIA Pharmaceuticals ACCESSWIRE
Nov-27-18 11:14AM  Raymond James Sees $1B Potential In Loxo Oncology's Vitrakvi, LOXO-95 Benzinga -8.91%
08:54AM  Bayer's TRK Inhibitor Gets FDA Nod for Advanced Solid Tumors Zacks
06:55AM  Today's Research Reports on Trending Tickers: Halozyme Therapeutics and Loxo Oncology ACCESSWIRE
12:47AM  [$$] Bayer/Loxo: gene machine Financial Times
Nov-26-18 08:32PM  Loxo, Bayer drug for cancers driven by rare mutation gets U.S. nod Reuters
07:16PM  FDA Approves Vitrakvi® (larotrectinib), the First Ever TRK Inhibitor, for Patients with Advanced Solid Tumors Harboring an NTRK Gene Fusion(1,2) GlobeNewswire
05:41PM  Loxo, Bayer drug for cancers driven by rare mutation gets U.S. nod Reuters
Nov-16-18 07:00AM  Today's Research Reports on Trending Tickers: Loxo Oncology and Halozyme Therapeutics ACCESSWIRE
Nov-14-18 03:36AM  Edited Transcript of LOXO earnings conference call or presentation 8-Nov-18 1:00pm GMT Thomson Reuters StreetEvents -9.84%
Nov-08-18 08:45AM  Loxo Oncology (LOXO) Reports Q3 Loss, Lags Revenue Estimates Zacks
07:39AM  Loxo: 3Q Earnings Snapshot Associated Press
06:45AM  Loxo Oncology Reports Third Quarter 2018 Financial Results GlobeNewswire
Nov-06-18 06:45AM  Loxo Oncology to Participate in Upcoming Investor Conferences GlobeNewswire
Nov-05-18 07:00AM  Today's Research Reports on Trending Tickers: Loxo Oncology and Cronos Group ACCESSWIRE
Nov-02-18 08:00AM  Today's Research Reports on Trending Tickers: Loxo Oncology and Auris Medical Holding ACCESSWIRE
Nov-01-18 06:45AM  Loxo Oncology to Announce Third Quarter 2018 Financial Results GlobeNewswire +7.62%
Oct-23-18 08:21AM  Why Investors Are Paying a Premium for These 3 Biotech Stocks Motley Fool
Oct-22-18 04:26PM  These Companies Are Dragging Biotech Stocks Into A Pit On Cancer Tests Investor's Business Daily
Oct-21-18 05:30AM  Roche takes on Loxo, Bayer in gene-defined cancer class Reuters
05:12AM  Roche takes on Loxo, Bayer in gene-defined cancer class Reuters
05:12AM  Loxo Oncology Announces Larotrectinib Clinical Update in Patients with TRK Fusion Cancers at the European Society for Medical Oncology 2018 Congress GlobeNewswire
05:12AM  Larotrectinib Delivers 81% Overall Response Rate in an Expanded Dataset of 109 TRK Fusion Cancer Patients Across Ages and Tumor Types PR Newswire
Oct-19-18 08:20AM  Research Report Identifies Loxo Oncology, Atrion, Alexander's, Broadridge Financial Solutions, International Flavors & Fragrances, and Conagra Brands with Renewed Outlook Fundamental Analysis, Calculating Forward Movement GlobeNewswire
Oct-16-18 06:33AM  3 Biotechs Awaiting FDA Approval Decisions Motley Fool +6.94%
Oct-15-18 06:45AM  Loxo Oncology Announces Receipt of Breakthrough Therapy Designation from U.S. Food and Drug Administration for LOXO-292 for the Treatment of RET Fusion-Positive Thyroid Cancer GlobeNewswire
Oct-09-18 06:45AM  Loxo Oncology Announces Details for Data Presentations at the European Society for Medical Oncology 2018 Congress GlobeNewswire
Oct-06-18 09:05AM  Loxo Oncology Announces LOXO-292 Durability Update in Patients with RET-Mutant Medullary Thyroid Cancer and RET Fusion-Positive Thyroid Cancer from LIBRETTO-001 at the 88th Annual Meeting of the American Thyroid Association GlobeNewswire
Sep-28-18 07:37AM  Best ETFs for 2018: Dont Sweat This Quarter for the SBIO ETF InvestorPlace
Sep-25-18 04:20PM  Loxo Oncology Announces LOXO-292 Durability Update in Patients with RET Fusion-Positive Non-Small Cell Lung Cancer from LIBRETTO-001 at the IASLC 19th World Conference on Lung Cancer GlobeNewswire
Sep-18-18 06:45AM  Loxo Oncology Announces Accepted Abstracts at the 88th Annual Meeting of the American Thyroid Association GlobeNewswire
Sep-13-18 08:45AM  3 Lung Cancer Stocks That Could End September on a High Note Motley Fool
Sep-06-18 04:14PM  5 Health Care Stocks in Gurus' Portfolios GuruFocus.com
Sep-05-18 09:55AM  Bayer open for drug licensing deals, cutting debt remains priority Reuters
06:45AM  Loxo Oncology Announces Receipt of Breakthrough Therapy Designation from U.S. Food and Drug Administration for LOXO-292 GlobeNewswire
Sep-02-18 09:33AM  3 Biotech Stocks That Could Soar in September Motley Fool
Aug-29-18 06:45AM  Loxo Oncology to Present at Upcoming Investor Conferences GlobeNewswire
Aug-28-18 04:00AM  Edited Transcript of LOXO earnings conference call or presentation 9-Aug-18 12:00pm GMT Thomson Reuters StreetEvents
Aug-27-18 02:30AM  Loxo Oncology Announces Submission of European Marketing Authorization Application for Larotrectinib GlobeNewswire
Aug-10-18 04:30PM  Loxo Oncology Announces Accepted Abstracts at the IASLC 19th World Conference on Lung Cancer GlobeNewswire
Aug-09-18 08:10AM  Loxo Oncology (LOXO) Reports Q2 Loss, Tops Revenue Estimates Zacks -7.18%
07:04AM  Loxo: 2Q Earnings Snapshot Associated Press
06:45AM  Loxo Oncology Reports Second Quarter 2018 Financial Results GlobeNewswire
06:00AM  Loxo Oncology Inc to Host Earnings Call ACCESSWIRE
Aug-08-18 09:18AM  Drug/Biotech Stock Q2 Earnings on Aug 9: PRGO, BDSI & More Zacks
Aug-02-18 06:45AM  Loxo Oncology to Announce Second Quarter 2018 Financial Results GlobeNewswire
Jul-17-18 07:35AM  Breakfast Technical Briefing on Mirati Therapeutics and Three Other Additional Biotech Stocks ACCESSWIRE
Jul-11-18 08:10AM  Today's Research Reports on Stocks to Watch: Loxo Oncology and OnoCyte ACCESSWIRE
Jun-20-18 12:00AM  Finding Cancer Patients Is Pharma Industry's Unlikely Challenge Bloomberg
Jun-11-18 08:20AM  Today's Research Reports on Trending Tickers: Loxo Oncology and Geron Corporation ACCESSWIRE
Jun-08-18 08:47AM  Here's Why Loxo Oncology Stock Gained 40.8% in May Motley Fool
06:04AM  3 Cancer Stocks That Could Soar in the Second Half of 2018 Motley Fool
Jun-07-18 08:10AM  New Research Coverage Highlights Durect, Credit Suisse Group, Obsidian Energy, TransCanada, Golden Star Resources, and Loxo Oncology Consolidated Revenues, Company Growth, and Expectations for 2018 GlobeNewswire
Jun-04-18 04:23PM  Why #ASCO18 Caused Blueprint Medicines Shares To Tumble Up to 16% Today Motley Fool
04:21PM  Here Are Winners And Losers From 2018's Biggest Cancer Drug Meeting Investor's Business Daily
03:32PM  Merck emerges as key winner at ASCO conference CNBC Videos
01:18PM  5 Biotech Stocks Moving On ASCO Presentations Benzinga
12:45PM  Loxo CEO on genetically targeted cancer drugs CNBC Videos
09:40AM  Merck Leads Dow As Stocks Move Higher: These 2 China Names Advance Investor's Business Daily
09:36AM  Loxo shares surge 8% on early-stage cancer drug trial MarketWatch
09:00AM  Options Traders Expect Huge Moves in Loxo Oncology (LOXO) Stock Zacks
08:05AM  Dow Jones Futures Lead Gains: These 6 Stocks Are In Focus Today Investor's Business Daily
07:00AM  Five key takeaways from ASCO, the world's largest cancer research conference CNBC
Jun-03-18 02:10PM  #ASCO18: A Weekend of Surprises Motley Fool
11:25AM  These 4 Hot Nasdaq Stocks Blasted To New All-Time Highs Last Week Forbes
Jun-02-18 10:17AM  Loxo Scores A Success With Second Targeted Cancer Drug Forbes
09:00AM  Loxo Promised Improved Data For Experimental Cancer Drug And Delivers Investor's Business Daily
09:00AM  Loxo Oncology Announces Positive Interim Clinical Data from LOXO-292 Dose Escalation Trial in RET-Altered Cancers Presented at the American Society of Clinical Oncology Annual Meeting GlobeNewswire
08:52AM  New Data Helps Loxo's Cause in Developing Targeted Cancer Drugs Bloomberg
08:00AM  Loxo Oncology posts improved results for newest cancer drug Reuters
Jun-01-18 04:40PM  Conquering cancer in the Windy City CNBC Videos +5.28%
May-31-18 06:01PM  The Big Thing to Watch at ASCO 2018 Motley Fool
11:53AM  Loxo Oncology's Candidates Are 'Impressive,' Piper Jaffray Says In Bullish Initiation Benzinga
May-29-18 07:34AM  Loxo-Bayer cancer drug gets priority review from FDA Reuters
06:45AM  FDA Accepts Larotrectinib New Drug Application and Grants Priority Review PR Newswire
06:45AM  FDA Accepts Larotrectinib New Drug Application and Grants Priority Review GlobeNewswire
May-19-18 09:32AM  Does a Blue Ribbon Make This Biotech Stock a Buy Now? Motley Fool
May-18-18 04:51PM  Winners and Losers From the Biggest Cancer Meeting of the Year (So Far) Motley Fool
10:16AM  This Tiny Cancer Drug Upstart Just Got Even More Interesting Motley Fool
08:10AM  Todays Research Reports on Stocks to Watch: Loxo Oncology and Jounce Therapeutics ACCESSWIRE
May-17-18 01:52PM  Here's Why Loxo Oncology Rose as Much as 23.3% Today Motley Fool +20.09%
10:39AM  Loxo Oncology shares surge 21% on preview of cancer drug trial data MarketWatch
09:31AM  Benzinga Pro's 5 Stocks To Watch Today Benzinga
09:19AM  UPDATE 1-Loxo Oncology's targeted RET drug shows promise in early trial Reuters
07:15AM  Dow Jones Futures Today: These 2 Tech Stocks Near Buys Move On Earnings; This Biotech Soars Investor's Business Daily
May-16-18 05:38PM  After-hours buzz: CSCO, JACK & more CNBC
05:18PM  Loxo Oncology's targeted RET drug shows promise in early trial Reuters
05:00PM  Loxo Oncology Announces Details of LOXO-292 Clinical Data Presentations at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting GlobeNewswire
May-15-18 03:52PM  Edited Transcript of LOXO earnings conference call or presentation 8-May-18 12:00pm GMT Thomson Reuters StreetEvents
May-08-18 06:45AM  Loxo Oncology Reports First Quarter 2018 Financial Results GlobeNewswire
May-07-18 04:30PM  Loxo Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
May-01-18 06:45AM  Loxo Oncology to Announce First Quarter 2018 Financial Results GlobeNewswire
Apr-24-18 08:27AM  How Blueprint Medicines Got The Blues Forbes
Apr-17-18 11:41AM  Loxo Oncology (LOXO) Shares March Higher, Can It Continue? Zacks
08:10AM  Todays Research Reports on Stocks to Watch: Clovis Oncology and Loxo Oncology ACCESSWIRE
Apr-16-18 09:52AM  Morgan Stanley Upgrades Loxo On The Potential Of A Targeted Cancer Therapy Benzinga +8.50%
Apr-12-18 07:45AM  Investor Expectations to Drive Momentum within Loxo Oncology, Kinross Gold, Marlin Business Services, lululemon athletica inc, LG Display Co., and QIWI Discovering Underlying Factors of Influence GlobeNewswire
Loxo Oncology, Inc., a biopharmaceutical company, develops and sells medicines for patients with genetically defined cancers in the United States. Its lead product candidate comprises larotrectinib, an oral selective inhibitor of tropomyosin receptor kinase (TRK), which is in adult Phase 1 trial, a pediatric Phase 1/2 trial, and an adult/adolescent Phase 2 trial for the treatment of patients with tumor types, such as lung, head and neck, melanoma, colorectal, sarcoma, and breast cancer. The company's preclinical programs include LOXO-195, a drug candidate in preclinical development to address predicted acquired resistance mechanisms; RET inhibitor that optimizes potency for rearranged during transfection (RET) fusion proteins, mutations, and anticipated mechanisms of acquired resistance; and FGFR inhibitor that enables potently inhibiting FGFR isoforms comprising four isoforms with tyrosine kinase domains. It has a drug discovery collaboration agreement with Array BioPharma, Inc. to obtain various rights to TRK inhibitor program and oncology targets; strategic partnership with Illumina, Inc. to develop and commercialize a multi-gene panel for broad tumor profiling; and research collaboration agreement with Veracyte, Inc. to develop medicines for patients with genetically defined cancers. Loxo Oncology, Inc. was founded in 2013 and is headquartered in Stamford, Connecticut.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Bilenker Joshua H.President & CEONov 27Option Exercise13.6710,000136,700174,407Nov 28 05:08 PM
Burstein JenniferSenior VP of FinanceNov 27Option Exercise11.351,25014,1881,250Nov 28 05:09 PM
Van Naarden JacobChief Business OfficerNov 27Option Exercise8.234,50037,03118,200Nov 28 05:13 PM
Bilenker Joshua H.President & CEONov 27Sale141.3410,0001,413,418164,407Nov 28 05:08 PM
Burstein JenniferSenior VP of FinanceNov 27Sale142.281,250177,8510Nov 28 05:09 PM
Van Naarden JacobChief Business OfficerNov 27Sale141.664,500637,48113,700Nov 28 05:13 PM
Bilenker Joshua H.President & CEONov 26Option Exercise2.2039,00085,709174,407Nov 28 05:08 PM
Burstein JenniferSenior VP of FinanceNov 26Option Exercise11.351,25014,1881,250Nov 28 05:09 PM
Van Naarden JacobChief Business OfficerNov 26Option Exercise3.655,50020,06419,200Nov 28 05:13 PM
Bilenker Joshua H.President & CEONov 26Sale153.1810,0001,531,829164,407Nov 28 05:08 PM
Burstein JenniferSenior VP of FinanceNov 26Sale153.081,250191,3560Nov 28 05:09 PM
Van Naarden JacobChief Business OfficerNov 26Sale153.135,500842,22413,700Nov 28 05:13 PM
Bilenker Joshua H.President & CEOOct 04Option Exercise3.6510,00036,480145,407Oct 05 04:42 PM
Burstein JenniferSenior VP of FinanceOct 04Option Exercise11.351,25014,1881,250Oct 05 04:44 PM
Van Naarden JacobChief Business OfficerOct 04Option Exercise3.654,50016,41618,200Oct 05 04:46 PM
Bilenker Joshua H.President & CEOOct 04Sale162.6210,0001,626,246135,407Oct 05 04:42 PM
Burstein JenniferSenior VP of FinanceOct 04Sale162.641,250203,3040Oct 05 04:44 PM
Van Naarden JacobChief Business OfficerOct 04Sale162.644,500731,88413,700Oct 05 04:46 PM
Burstein JenniferSenior VP of FinanceOct 03Option Exercise11.351,25014,1881,250Oct 05 04:44 PM
Van Naarden JacobChief Business OfficerOct 03Option Exercise3.655,50020,06419,200Oct 05 04:46 PM
Bilenker Joshua H.President & CEOOct 03Sale168.187,0951,193,254135,407Oct 05 04:42 PM
Burstein JenniferSenior VP of FinanceOct 03Sale167.201,250208,9960Oct 05 04:44 PM
Van Naarden JacobChief Business OfficerOct 03Sale167.165,500919,37813,700Oct 05 04:46 PM
Kunkel Lori AnneDirectorOct 01Option Exercise3.655,00018,2405,000Oct 03 05:05 PM
Kunkel Lori AnneDirectorOct 01Sale170.375,000851,8290Oct 03 05:05 PM
Van Naarden JacobChief Business OfficerSep 13Option Exercise3.654,50016,41618,200Sep 14 06:14 PM
Bilenker Joshua H.President & CEOSep 13Option Exercise1.8110,00018,067145,407Sep 14 06:17 PM
Burstein JenniferSenior VP of FinanceSep 13Option Exercise11.351,25014,1881,250Sep 14 06:19 PM
Van Naarden JacobChief Business OfficerSep 13Sale165.984,500746,90313,700Sep 14 06:14 PM
Bilenker Joshua H.President & CEOSep 13Sale165.9810,0001,659,805135,407Sep 14 06:17 PM
Burstein JenniferSenior VP of FinanceSep 13Sale166.021,250207,5230Sep 14 06:19 PM
Van Naarden JacobChief Business OfficerSep 12Option Exercise3.655,50020,06419,200Sep 14 06:14 PM
Bilenker Joshua H.President & CEOSep 12Option Exercise1.1810,00011,840145,407Sep 14 06:17 PM
Burstein JenniferSenior VP of FinanceSep 12Option Exercise11.351,25014,1881,250Sep 14 06:19 PM
Van Naarden JacobChief Business OfficerSep 12Sale166.605,500916,27613,700Sep 14 06:14 PM
Bilenker Joshua H.President & CEOSep 12Sale166.4210,0001,664,159135,407Sep 14 06:17 PM
Burstein JenniferSenior VP of FinanceSep 12Sale167.891,250209,8690Sep 14 06:19 PM
Bilenker Joshua H.President & CEOAug 14Option Exercise1.1810,00011,840145,407Aug 15 05:23 PM
Burstein JenniferSenior VP of FinanceAug 14Option Exercise11.351,25014,1881,250Aug 15 05:25 PM
Van Naarden JacobChief Business OfficerAug 14Option Exercise3.654,50016,41618,200Aug 15 05:27 PM
Bilenker Joshua H.President & CEOAug 14Sale159.9110,0001,599,089135,407Aug 15 05:23 PM
Burstein JenniferSenior VP of FinanceAug 14Sale160.221,250200,2790Aug 15 05:25 PM
Van Naarden JacobChief Business OfficerAug 14Sale159.924,500719,64213,700Aug 15 05:27 PM
Bilenker Joshua H.President & CEOAug 13Option Exercise1.1810,00011,840145,407Aug 15 05:23 PM
Burstein JenniferSenior VP of FinanceAug 13Option Exercise11.351,25014,1881,250Aug 15 05:25 PM
Van Naarden JacobChief Business OfficerAug 13Option Exercise3.655,50020,06419,200Aug 15 05:27 PM
Burstein JenniferSenior VP of FinanceAug 13Sale158.261,250197,8270Aug 15 05:25 PM
Bilenker Joshua H.President & CEOAug 13Sale158.9110,0001,589,092135,407Aug 15 05:23 PM
Van Naarden JacobChief Business OfficerAug 13Sale158.875,500873,80413,700Aug 15 05:27 PM
Bilenker Joshua H.President & CEOJul 10Option Exercise1.187,5008,880142,907Jul 11 05:01 PM
Van Naarden JacobChief Business OfficerJul 10Option Exercise3.651,5415,62215,241Jul 11 05:03 PM
AISLING CAPITAL III LP10% OwnerJul 10Sale179.431,400,000251,202,0002,038,920Jul 12 04:45 PM
Van Naarden JacobChief Business OfficerJul 10Sale179.691,541276,90713,700Jul 11 05:03 PM
Bilenker Joshua H.President & CEOJul 10Sale179.727,5001,347,923135,407Jul 11 05:01 PM
Bilenker Joshua H.President & CEOJul 09Option Exercise1.187,5008,880142,907Jul 11 05:01 PM
Van Naarden JacobChief Business OfficerJul 09Option Exercise3.651,5415,62215,241Jul 11 05:03 PM
Burstein JenniferSenior VP of FinanceJul 09Option Exercise11.351,50017,0251,500Jul 11 05:04 PM
Burstein JenniferSenior VP of FinanceJul 09Sale187.251,500280,8700Jul 11 05:04 PM
Van Naarden JacobChief Business OfficerJul 09Sale187.301,541288,63113,700Jul 11 05:03 PM
Bilenker Joshua H.President & CEOJul 09Sale187.237,5001,404,241135,407Jul 11 05:01 PM
Bilenker Joshua H.President & CEOJun 20Option Exercise1.1835,50042,032163,207Jun 21 05:02 PM
Van Naarden JacobChief Business OfficerJun 20Option Exercise3.6513,54149,39813,541Jun 21 05:03 PM
Van Naarden JacobChief Business OfficerJun 20Sale179.341,541276,37012,000Jun 21 05:03 PM
Bilenker Joshua H.President & CEOJun 20Sale179.3321,0003,765,8328,000Jun 21 05:02 PM
Bilenker Joshua H.President & CEOJun 20Sale179.257,5001,344,405155,707Jun 21 05:02 PM
Bilenker Joshua H.President & CEOJun 19Option Exercise1.187,5008,880135,207Jun 21 05:02 PM
Van Naarden JacobChief Business OfficerJun 19Option Exercise3.651,5415,6221,541Jun 21 05:03 PM
Burstein JenniferSenior VP of FinanceJun 19Option Exercise11.351,70019,2951,700Jun 21 05:04 PM
Burstein JenniferSenior VP of FinanceJun 19Sale176.991,700300,8880Jun 21 05:04 PM
Van Naarden JacobChief Business OfficerJun 19Sale176.941,541272,6660Jun 21 05:03 PM
Bilenker Joshua H.President & CEOJun 19Sale178.2521,0003,743,35329,000Jun 21 05:02 PM
Bilenker Joshua H.President & CEOJun 19Sale177.047,5001,327,766127,707Jun 21 05:02 PM
Kunkel Lori AnneDirectorJun 15Sale176.866,8401,209,6890Jun 18 05:00 PM
Kunkel Lori AnneDirectorJun 14Option Exercise6.5432,392211,70839,232Jun 18 05:00 PM
Kunkel Lori AnneDirectorJun 14Sale180.4632,3925,845,5646,840Jun 18 05:00 PM
Fuhrman AlanDirectorJun 08Option Exercise11.352,62529,7942,625Jun 11 06:01 PM
MAYLEBEN TIMOTHY MDirectorJun 08Option Exercise21.7510,000217,55010,000Jun 11 06:02 PM
MAYLEBEN TIMOTHY MDirectorJun 08Sale179.5510,0001,795,4690Jun 11 06:02 PM
Fuhrman AlanDirectorJun 08Sale178.072,625467,4370Jun 11 06:01 PM
Flaherty Keith T.DirectorJun 07Option Exercise1.1850,00059,20059,732Jun 11 06:00 PM
Flaherty Keith T.DirectorJun 07Sale173.5450,0008,677,0279,732Jun 11 06:00 PM
Bilenker Joshua H.President & CEOMay 15Option Exercise1.187,5008,880190,207May 16 04:44 PM
Van Naarden JacobChief Business OfficerMay 15Option Exercise3.651,5415,6221,541May 16 04:46 PM
Van Naarden JacobChief Business OfficerMay 15Sale137.291,541211,5660May 16 04:46 PM
Bilenker Joshua H.President & CEOMay 15Sale137.417,5001,030,575182,707May 16 04:44 PM
Bilenker Joshua H.President & CEOMay 14Option Exercise1.187,5008,880190,207May 16 04:44 PM
Van Naarden JacobChief Business OfficerMay 14Option Exercise3.651,5415,6221,541May 16 04:46 PM
Burstein JenniferSenior VP of FinanceMay 14Option Exercise11.351,70019,2951,700May 16 04:45 PM
Burstein JenniferSenior VP of FinanceMay 14Sale136.931,700232,7840May 16 04:45 PM
Van Naarden JacobChief Business OfficerMay 14Sale137.541,541211,9490May 16 04:46 PM
Bilenker Joshua H.President & CEOMay 14Sale135.617,5001,017,071182,707May 16 04:44 PM
Bilenker Joshua H.President & CEOApr 25Option Exercise1.187,5008,880190,207Apr 26 04:31 PM
Van Naarden JacobChief Business OfficerApr 25Option Exercise3.651,5415,6221,541Apr 26 04:32 PM
Van Naarden JacobChief Business OfficerApr 25Sale130.801,541201,5630Apr 26 04:32 PM
Bilenker Joshua H.President & CEOApr 25Sale130.867,500981,423182,707Apr 26 04:31 PM
Bilenker Joshua H.President & CEOApr 24Option Exercise1.187,5008,880190,207Apr 26 04:31 PM
Van Naarden JacobChief Business OfficerApr 24Option Exercise3.651,5415,6221,541Apr 26 04:32 PM
Burstein JenniferSenior VP of FinanceApr 24Option Exercise11.351,70019,2951,700Apr 26 04:33 PM
Burstein JenniferSenior VP of FinanceApr 24Sale131.651,700223,8050Apr 26 04:33 PM
Van Naarden JacobChief Business OfficerApr 24Sale131.671,541202,8980Apr 26 04:32 PM